Key result
Antithrombotic therapy during breast cancer surgery did not significantly increase postoperative bleeding complications compared to no antithrombotic therapy (12.0% vs. 3.5%, p=0.360).
Why the study?
Does antithrombotic therapy increase postoperative bleeding or thromboembolic complications in patients undergoing breast cancer surgery?
Cohort (n=193)
No
Does antithrombotic therapy increase postoperative bleeding or thromboembolic complications in patients undergoing breast cancer surgery?
Absolute Event Rate: 12% vs 3.5%
p-value: p=0.360
Breast cancer surgery can be safely performed in patients on antithrombotic therapy with appropriate perioperative management, without a significant increase in bleeding or thromboembolic events.
Suggests safe perioperative ATT management in breast cancer surgery; leaves open need for prospective validation.
AIM: The aim of the study was to assess the safety of surgery for breast cancer in patients with antithrombotic therapy (ATT), including antiplatelet therapy (APT) and anticoagulation therapy (ACT) for thromboembolic risks. METHODS: One hundred ninety-three consecutive patients receiving breast surgery for breast cancer at our institution between 2010 and 2015 were retrospectively reviewed. Among them, ATT was regularly used in 50 patients (25.9%). Our perioperative management included maintenance of preoperative aspirin monotherapy for APT and bridging heparin for ACT in patients at high thromboembolic risks and early postoperative reinstitution in all ATT cases. The outcome variables of patients with ATT (ATT group) were compared to those of patients without ATT (non-ATT group), and the significant risk factors for postoperative complications were determined by multivariate analysis. RESULTS: This series included 127 mastectomy and 66 breast-conserving surgery. ATT group showed significantly high frequency of history of cerebral infarction and percutaneous coronary intervention (PCI). In the ATT group, 32 patients (16.6%) were categorized as high risk for thromboembolism, but there was neither thromboembolic event nor perioperative death in the whole cohort. Surgical blood loss and rates of intraoperative transfusion were identical between the groups. Whereas overall postoperative bleeding complication was more frequently observed in the ATT group compared to the non-ATT group (12.0% vs. 3.5%, p=0.360) in univariate analyses, multivariate analysis showed that neither ATT nor preoperative aspirin continuation affected postoperative bleeding complications. CONCLUSION: Even in patients undergoing ATT, surgery for breast cancer is safely performed without any increase in blood loss or postoperative bleeding, and no thromboembolism was experienced in the series. Our perioperative management of ATT patients is valid during breast surgery, although this patient population is still challenging and should be rigorously managed.
No takes yet. Share an insight, caveat, or question.
Emoto et al. (2017) conducted a cohort in Breast cancer (n=193). Antithrombotic therapy vs. No antithrombotic therapy was evaluated on Overall postoperative bleeding complication (p=0.360). Antithrombotic therapy during breast cancer surgery did not significantly increase postoperative bleeding complications compared to no antithrombotic therapy (12.0% vs. 3.5%, p=0.360).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: